Technologies

Technology Description

This technology opportunity provides a method for detecting CTIP2 or CTIP2L and for their use as biomarkers for squamous cell carcinoma. This technology can be used to develop kits for detecting SCC in a patient. The kit can include a CTIP2 and CTIP2L -specific antibody, oligonucleotides, or primers, and a chart or diagram showing biomarker expression values that are expected in the presence of SCC (or a particular stage of SCC). An increase in expression of at least 2-fold relative to a reference value for a sample negative for SCC indicates the presence of SCC in the sample obtained from the subject.

Background of Invention

Squamous cell carcinoma (SCC) is a malignant tumor that occurs in many different organs, including the skin, lips, mouth, esophagus, head and neck, urinary bladder, prostate, lungs, breast, vagina, cervix, and ovaries. The current state diagnosing SCC requires a skin biopsy and examination under a microscope.